PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients

Background: Bevacizumab-based regimens are used as standard treatments for colorectal cancer. Unfortunately, there are no established predictive markers for bevacizumab response. Methods: Tumor samples from 36 metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy were anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Hung-Chih, Lapke, Nina, Chen, Shu-Jen, Lu, Yen-Jung, Jhou, Ren-Shiang, Yeh, Chien-Yuh, Tsai, Wen-Sy, Hung, Hsin-Yuan, Hsieh, Jason Chia-Hsun, Yang, Tsai-Sheng, Thiam, Tan Kien, You, Jeng-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162606/
https://www.ncbi.nlm.nih.gov/pubmed/30200630
http://dx.doi.org/10.3390/cancers10090314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162606/
https://www.ncbi.nlm.nih.gov/pubmed/30200630
http://dx.doi.org/10.3390/cancers10090314

Ejemplares similares